ArticleCancers2023

Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer.

Takafumi Mie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.